Global Red Biotechnology Market is expected to grow with an impressive CAGR in the forecast period of 2024-2028. This can be attributed to factors such as the growing demand for genetic engineering, the development of new medicines for the treatment of life-threatening diseases, and the increased production of precision medicine.

Red Biotechnology focuses on the therapeutic or diagnostic use of living cells and their components to develop novel medical treatments and cures for diseases and health issues. It includes the creation of a wide range of goods, including medicines, diagnostic instruments, vaccines, gene treatments, and other products for the treatment and prevention of different diseases.

The growing demand for precision medicine is enhancing the market opportunities and increasing demand for the global red biotechnology market.

Growing Demand for Genetic Engineering
An increase in demand for genetic engineering has been observed due to an increase in biologic drugs. According to IQVIA Institute data, biologic drugs represented 2 percent of all United States prescriptions but comprised 37% net drug spending. The growing use of genetic engineering, such as recombinant DNA technology, in creating genetically modified organisms, such as therapeutic antibodies, is propelling the growth of the red biotechnology market across the globe. The technologies, such as gene editing, such as CRISPR-based genetic editing, are also becoming much prevalent in the market and thereby are supporting the market growth by expanding the applications of red biotechnology in genetic engineering. Additionally, red biotechnology is found to have applications in the production of spinal discs, artificial bones, skin, and cartilage through tissue engineering techniques.

Development of new medicines for the treatment of life-threatening diseases
Red biotechnology has found applications in fields such as gene therapy, clinical trials, diagnostics, and research. Also, the growing number of clinical trials for the development of drugs, along with the rise in acceptance and demand for biosimilars, affect the growth of red biotechnology in the recent scenario. The expansion of the biopharmaceutical sector of the red biotechnology market is expected to grow with increasing clinical trials in medicine production. For instance, In July 2022, Replay-a genomic medicine-producing startup, invested USD55 million in a seed funding round to develop and transform genomic medicine through an interlinking stage for developing various genotype genomic research to discover new disease targets and enhance and improve the disease diagnosis & treatment.

Increased production of precision medicine
The growing prevalence of chronic diseases across the world is creating a rising demand for precision medicine. According to the World Health Organization (WHO), cancer is the second leading cause of death globally and has recorded around 9.6 million deaths globally. With the increasing number of cancer patients worldwide, the growth of the red biotechnology market is also expanding as it is utilized for diagnosing the reason for these diseases by using genetic testing and sequencing techniques, etc., and thereby has found many lucrative opportunities in diagnosis, drug development and treatment for diseases such as cancer and is thereby expected to bolster market growth in the forecast period. Along with this, red biotechnology is utilized in combined vaccine production, such as Hepatitis B, merged with the polio vaccine, and DPT merged with Hepatitis A, and this all together is of great importance to support the market growth in the forecast period.

Recent Development
In June 2022, Bluebird Bio developed a new gene therapy that is being evaluated by the United States Food Drug and Administration regarding the treatment of (CALD) cerebral adrenoleukodystrophy (a genetic condition that damages the membrane myelin sheath of the brain) in patients under adolescent age.


Market Segmentation
Global Red Biotechnology Market is segmented based on the product type, application, end-user, region, and competitive landscape. Based on product type, the market is segmented into diagnostic reagents, human vaccines, blood products, gene recombinant drugs, and others. Based on application, the market is segmented into biopharmaceutical production, gene therapy, genetic testing, pharmacogenomics, drug discovery, and others. Based on end-user, the market is segmented into pharmaceutical and biotechnology companies, CMO & CRO, research institutes, and others.


Market Players
Pfizer, Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche, Ltd., Bruker, Merck KGaA, Celgene Corporation, Amgen, Inc., etc., are some of the major players operating in the Global Red Biotechnology Market.


Report Scope:
In this report, Global Red Biotechnology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
• Red Biotechnology Market, By Product Type:
  –Diagnostic Reagents
  –Human Vaccines
  –Blood Products
  –Gene Recombinant drugs
  –Others
• Red Biotechnology Market, By Application:
  –Biopharmaceutical Production
  –Gene Therapy
  –Genetic Testing
  –Pharmacogenomics
  –Drug Discovery
  –Others
• Red Biotechnology Market, By End-User:
  –Pharmaceutical and Biotechnology companies
  –CMO & CRO
  –Research Institute
  –Others
• Red Biotechnology Market, By Region:
  –North America
   · United States
   · Canada
   · Mexico
  –Europe
   · Germany
   · France
   · United Kingdom
   · Italy
   · Spain
  –Asia-Pacific
   · China
   · Japan
   · India
   · South Korea
   · Australia
  –Middle East & Africa
   · South Africa
   · Saudi Arabia
   · UAE
   · Kuwait
  –South America
   · Brazil
   · Argentina
   · Colombia

Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Red Biotechnology Market.


Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information
• Detailed analysis and profiling of additional market players (up to five).